Psychiatrist Hurt by Drugs He Prescribed Challenges the Whole Profession

Overview

The video features Dr. Yseph introducing Australian psychiatrist Dr. Mark Horowitz, presenting his “groundbreaking” book Mudsley’s Deprescribing Guidelines (the subtitles contain errors, including “guidelines for moral prescription,” i.e., “Mudsley guidelines”).

The central claim is that psychiatrists and prescribers lack authoritative, institution-backed guidance for deprescribing psychiatric drugs—especially antidepressants and related classes. This gap allegedly leads to widespread, poorly recognized harm from withdrawal, including prolonged withdrawal (“prolonged withdrawal injury”).

Horowitz’s personal account and evidence-gathering

• Horowitz says he discovered late in training that antidepressants can cause withdrawal effects, contrasting them with better-known withdrawal-inducing drugs such as opioids and benzodiazepines.
• After deciding to stop an antidepressant he’d taken for about 15 years (he reports tapering over about 4 months using a liquid formulation), he describes what he calls the “most hellish experience” of his life:
  • near-continuous panic/terror (up to 12 hours/day)
  • severe insomnia/sleep disruption
  • dizziness
  • derealization/unreality
  • a need to “survive” day by day
• He reports that returning to the medication eventually helped him recover, but the episode drove him to investigate further.
• He says he first read high-level academic articles (from King’s College London) that portrayed discontinuation as “easy” with mild, self-limiting symptoms.
• He then searched online and found far more reports of severe or prolonged withdrawal than expected—claiming numbers rising into the thousands to tens of thousands. He argues this indicates a broader phenomenon, not a tiny “unlucky subset.”
• He later describes a “prescription cascade”: additional drugs were added for issues such as fatigue, memory/concentration problems, and sleepiness (including diagnoses described as narcolepsy), eventually worsening his functioning to the point where he considered leaving clinical work.

Horowitz’s long withdrawal and lasting impact

The video emphasizes that withdrawal harm can be prolonged and functionally disabling for years.

• In February 2024 (about 6 years after his 2018 taper began), Horowitz reports he is still tapering:
  • remaining on several medications
  • reaching extremely small doses
  • he mentions finishing tapering Lexapro after ~20 years, while still taking other drugs
• He describes ongoing cognitive and emotional difficulties (including confusion and poor concentration, plus dysphoria), reduced quality of life, and persistent symptoms such as depersonalization/derealization.
• He frames parts of his experience as “living life through a few inches of mud,” at times reduced to roughly 75% of normal functioning.

Purpose and structure of the book

Horowitz states the book aims to provide a practical, step-by-step manual for deprescribing psychiatric drug classes and managing withdrawal:

• Target audience
  • clinicians (e.g., GPs, psychiatrists, pharmacists, specialist nurses)
  • informed patients
• He argues that prior resources (e.g., the Ashton Handbook for benzodiazepines) may be dismissed as anecdotal.
• His claim is that his book is positioned as authoritative, evidence-based, and aligned with respected guideline authority.
• He stresses that tapering should be gradual and tailored, with special focus on the “last milligrams”, which he argues can have outsized effects.
• He says the book includes clinical descriptions of prolonged withdrawal injury and covers major classes, including:
  • antidepressants
  • benzodiazepines
  • “Z-drugs”
  • gabapentinoids

Advocacy goal: preventing “a hurricane of damage”

Horowitz argues that both emergency and routine clinical care often fail because withdrawal is misunderstood:

• Withdrawal is allegedly misdiagnosed and incorrectly reframed as relapse or an unrelated illness.
• People experiencing withdrawal are allegedly told “nothing is wrong.”
• Symptoms are then attributed to relapse or new conditions, leading to more medication, which he claims worsens the situation through additional prescribing.

Prolonged withdrawal vs relapse: central scientific critique

A major portion of the video challenges how “relapse prevention” trials are used to justify indefinite antidepressant maintenance.

• Horowitz/Joseph argue that relapse prevention studies often exclude or fail to adequately measure withdrawal effects.
• They describe typical relapse prevention trials as:
  1. patients in remission on antidepressants are randomized to continue vs stop
  2. relapse is measured using depression rating scales over 6–12 months
• Their argument: discontinuation—especially if rapid (sometimes within days)—can produce withdrawal symptoms that look like depression on rating scales, artificially inflating “relapse” in the discontinuation arm.
• They suggest the reported differences (e.g., ~40% relapse after stopping vs ~18% staying well/relapsing at lower rates while continuing) may substantially reflect withdrawal misclassified as relapse.
• Analogy: they use the smoking example—if quitting causes anxiety/irritability, interpreting that as justification to continue smoking is illogical; the correct interpretation is that quitting happened too fast and needs taper support.

Tolerance and adaptation

Horowitz further argues:

• Long-term use leads to tolerance to antidepressants (analogous to tolerance patterns seen with other drug classes).
• Since tolerance predicts withdrawal, antidepressants should not be assumed to provide durable benefit without adaptation.
• He frames long-term maintenance as potentially risky: even if symptoms don’t return immediately, adverse effects and withdrawal vulnerability may accumulate over time.

“When and why to prescribe”: narrower use and informed consent

The video does not argue “never use meds.” Instead, it pushes for more constrained prescribing and stronger consent practices:

• Short-term, crisis-oriented use
  • Horowitz compares antidepressants to benzodiazepines in the UK—used for limited duration to get through acute periods.
• Clear informed consent
  • acknowledging antidepressants may dull emotions and may lose effectiveness over time
  • acknowledging discontinuation can be difficult
• He argues that “chemical imbalance” narratives may mislead the public and clinicians into believing psychiatric drugs are inherently safe and corrective, rather than risk-bearing psychoactive interventions.

Broader framing: why the profession may not see what Horowitz sees

Horowitz proposes cultural and systemic reasons psychiatry may miss withdrawal harm:

• Psychiatry training may emphasize biological/technical explanations, making withdrawal effects “invisible” to clinicians trained to interpret them as relapse.
• He compares this to a psychological attention experiment (the “gorilla” study) to argue people often can’t notice what they aren’t trained to look for.
• He also suggests guidelines and literature may be “orchestrated” through selective evidence, industry influence, and career incentives.

Reception within psychiatry and possible change

• Horowitz claims younger clinicians show greater curiosity and practical interest in safe tapering.
• He describes more resistance from older clinicians who “never seen these problems” and may be reluctant to challenge mainstream practice publicly.
• He mentions a growing group of “critical psychiatrists” (he says nearly 500) who view psychiatric problems as life-related and drug-centric models as incomplete.
• He contrasts the UK and US:
  • UK guideline processes (in his view) are more constrained by public/government oversight
  • US processes have more industry involvement (in his view)

Call to action

• Horowitz urges doctors to use the book as a reliable deprescribing resource.
• He urges patients to advocate for themselves and discuss tapering details/formulations with clinicians.
• He promotes his website and the book’s availability (e.g., Amazon) and encourages reviews to help it become mainstream and influence prescribing norms.

Presenters / Contributors (as named in the subtitles)

• Dr. Yseph — host/introducer
• Dr. Mark Horowitz — guest psychiatrist; author of the deprescribing guidelines/book